IPO Details

About Company

Avience Biomedicals Ltd., incorporated in 2015, is a pioneering player in the biotechnology sector, focusing on the development and manufacturing of advanced biopharmaceuticals and diagnostic products. The company operates as part of the Avience Group, which has a strong reputation in the healthcare industry. Avience Biomedicals boasts a diverse product portfolio that includes monoclonal antibodies, recombinant proteins, and diagnostic kits, catering to both domestic and international markets. The company's state-of-the-art manufacturing facilities are located in Hyderabad, equipped with the latest bioprocessing technologies, enabling them to maintain high production capacities while adhering to stringent quality standards. Geographically, Avience has a robust presence, with distribution networks spanning across India, Europe, and North America, facilitating efficient delivery of its products to a wide customer base. As per the latest financials, Avience reported a total income of INR 150 crores, with a net profit of INR 20 crores, an EBITDA margin of 15%, ROCE of 12%, ROE of 10%, and a debt-equity ratio of 0.5. The company aims to utilize the proceeds from its IPO for expansion of manufacturing capabilities, research and development, and debt repayment, which is expected to enhance operational efficiency. Post-issue, the market capitalization is projected to be around INR 1,000 crores, with an earnings per share (EPS) of INR 10 and a price-to-earnings (P/E) ratio of 20. Investor sentiment appears optimistic, driven by the growing demand for biopharmaceuticals and the company's strategic growth plans.